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The core feature of trusts—holding property for the benefit of others—is well suited to constructing a research
community that treats reagents as public goods.ow
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 In 1980, with the passage of the U.S. Bayh-
Dole Act, the culture of academic science
changed. The act gave universities the re-
sponsibility to manage their intellectual
property for the betterment of society, with
the broad aim of translating more university
discoveries into products. In response, academic
institutions created technology transfer offices
to better manage their potential intellectual
property and facilitate technology commerciali-
zation (1). Predictably, as part of this more
sophisticated approach to technology transfer
and partly in response to metrics of success
that included numbers of patents, institutions
greatly expanded the range of discoveries that
they deemed to have potential commercial
interest (2). Discoveries were patented at rates
not seen previously, and assets such as bio-
medical research reagents were shared only un-
der legal material transfer agreements (MTAs)
that placed restrictions on their commercial
and, often, scientific use (3).
MTAs have three main functions. The first
is to establish clear “chains of custody,” thus
assuring the recipient that the material is not
encumbered by background agreements or
claims. The second is to provide legal protec-
tion for the provider. An MTA might include,
for example, a clause that states that there is
no guarantee that the material is actually safe
or fit for particular purposes. The third func-
tion is to establish conditions for use of the
material. For example, the provider might insert
conditions that restrict use or demand claims
on future intellectual property.
In aggregate, negotiations over such con-
ditions cause substantial delays in the dis-
tribution of research reagents. A university
might execute thousands of MTAs each year,with an average delay to execution of a few
weeks and with exceptional delays of months
and years. As a result, what was born as a so-
lution for the perceived translational gap be-
tween academia and industry has evolved
into a widely applied and complex system
of legal agreements that often encumber even
the most basic and commercially irrelevant
biomedical research (4). There are now stan-
dard template agreements that have stream-
lined the MTA process, but only a small
fraction of reagent exchange is done under
these standard MTAs. Examples of such
MTAs include the Uniform Biological Material
Transfer Agreement (www.autm.net/resources-
surveys/material-transfer-agreements/uniform-
biological-material-transfer-agreement) and
the U.K. Brunswick MTA (www.arma.ac.uk/
resources-1/research-contracts/material-transfer-
human-tissue-agreements).
In another attempt to accelerate science,
some projects were established to generate re-
search materials and make them available.
Most focus on those materials that have low
commercial potential and little chance of gen-
erating new intellectual property. For exam-
ple, the Mammalian Gene Collection project
created a repository of sequenced human com-
plementary DNA clones that were made avail-
able for a cost but without legal encumbrances
(5). Other reagent-generating projects, such as
the Structural Genomics Consortium (6) (www.
thesgc.org/chemical-probes), provide open
access to reagents that have considerable com-
mercial value and that also might be used to
generate patentable discoveries. The position
of the Structural Genomics Consortium is that
these reagents would make a greater impact if
kept in the public domain, and the patenting ofdiscoveries using these reagents would restrict
both subsequent scientific discovery and com-
mercial exploitation.
We sought to develop a general mecha-
nism to allow for the widest and least encum-
bered use of research reagents. The existing
standard MTAs restrict the recipient from
transferring the material to other scientists,
and they also place restrictions on the use
of the material commercially. To overcome
these limitations, we describe the concept of
an “open science trust” as a framework to share
research tools. The core feature of trusts—the
holding of property for the benefit of others—
is better suited than are bilateral contractual
arrangements to the construction of a research
community dedicated to treating experimental
reagents as public goods.THE TRUST DEVICE
Under an open science trust, reagents are treated
as a public-good resource governed by prin-
ciples that promote the public interest, in this
case, open science. Our open science trust
agreement codifies these public-good princi-
ples. Under its terms, a recipient of research
reagents becomes a “trustee” of the reagents.
Trustees are bound by principles that specifically
prohibit filing any patent claims that would re-
strict use of the reagents by others. The result is
to create and expand an open science commu-
nity connected by a common commitment to
the foundational aims of the reagent generators.
A trust is a legal relationship whereby one
party—called the trustee—is given control
over property but must use it for the benefit
of others—called the beneficiaries. In this re-
gard, a trust contrasts with direct legal owner-
ship over property, which allows owners to
use the property for their own ends and to
prevent others from using or benefiting from
it. That is how we normally think about tan-
gible goods such as real estate and intangible
ones such as patented biomedical inventions.
A trust places a duty on those who pos-
sess entrusted assets to manage those assets1 of 3
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 for the benefit of particular third parties or, in
the case of charitable trusts, in furtherance of
particular objects that benefit the public. Trusts
are created by appointing trustees under a legal
document that enumerates specific obligations
in dealing with trust property. Private trusts—
those with individual beneficiaries—are often
used for tax and estate planning purposes.
Charitable trusts, by contrast, are dedicated
to serving the public, as opposed to partic-
ular individuals, and must have definite char-
itable objects that guide the trustee’s use of
trust property. In effect, the “public” consti-
tutes the beneficiary of a charitable trust. Char-
itable trusts are often administered by a group
of trustees whose joint efforts to further the
aims of the trust can foster a communal sense
of purpose. at UNIVERSITY O
F N. CARO
LINA - CHAPEL HILL on August 16, 2019
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OPEN SCIENCE
The goal of our project is to provide the com-
munity with tools and reagents without restric-
tions on use. The open science trust concept
helps to achieve this end by appointing the re-
cipient of research reagents as a trustee of the
reagents, who commits to use them in a man-
ner that serves the trust’s beneficiaries. These
beneficiaries include (i) the organization that
provides the reagents, (ii) others in the scientif-
ic community who may benefit from open
access to the reagents and the results of the re-
cipient’s research, and (iii) members of the
general public whose health might be aided
by subsequent discoveries.
Whereas it is not, strictly speaking, a char-
itable trust, the open science trust mechanism
seeks to further open science principles for the
public good in a similar spirit. Just as a trust
document sets out particular conditions aimed
at furthering the trust’s goals, the open science
trust lists a series of specific obligations that the
trustee accepts, including (i) the duty to place
resulting research and data in the public do-
main and (ii) the duty not to seek or enforce
intellectual property rights. Moreover, because
the open science trust is not intended to inhibit
downstream innovation, it limits the enumer-
ated obligations to the supplied material itself;
the obligations do not extend to derivatives of
the material that the trustee might create.
These conditions were crafted to signal to
potential recipients that they must embrace
open science principles. As a result, the open
science trust achieves two objectives. First, it
allows a rapid means for researchers to access
and share enabling reagents. Second, it aggre-
gates a community of researchers around theEdwards et al., Sci. Transl. Med. 9, eaai9055 (2017) 31reagents, expanding the scope of open science
conducted with the reagents. The open science
trust differs in form and in spirit from the cus-
tomary mechanisms to transfer materials be-
tween institutions. When an MTA is used to
transfer materials, the reagents are treated as
commercial goods. Such transactional interac-
tions are often subject to lengthy negotiation
and also convey to the recipient a sense of in-
dividual ownership of the materials. By con-
trast, the open science trust fosters a sense of
community dedicated to serving the interests
of others.ENFORCING THE TRUST
Commonly, trusts are enforced through le-
gal mechanisms: private trusts through the
threat of lawsuit by the beneficiaries and
charitable trusts through the actions of gov-
ernment officials with jurisdiction over char-
ities. In our concept of an open science trust,
although its beneficiaries could, in theory,
seek redress for violations of the trust con-
ditions, we do not intend for this to occur.
We anticipate that the sense of community
among recipient trustees, and the norms that
are implicit, will become the mechanism to
enforce the trust. We believe that the open
science trust’s provision for sharing results
will evolve to become the expected practice
by the user community. In this context, pre-
cisely because the open science trust model
seeks to encourage a sense of communal par-
ticipation and to inculcate a set of shared
open science norms among researchers, a
trustee who does not abide by the terms of
the trust would potentially face challenges
to maintaining good standing within the
community. This, we imagine, will provide
stronger inducement to adhere to the prin-
ciples than would the threat of legal action.
The use of community norms to enforce
behavior has precedent. Norms, like law, serve
to promote cooperation in a community by
overcoming socially deleterious but individual-
ly rational conduct. Scholars have shown that
social norms play an important role in in-
ducing people to follow informal rules in a com-
munity. As the property scholar R. Ellickson
showed in a study of Shasta County ranchers,
members of a community are more likely to
obey their own informal laws than the official
laws on the books, so long as the community
stands behind and enforces those informal laws.
In Ellickson’s study, ranchers had their own
rules concerning responsibility for damage cre-
ated by escaped cattle, and they used communal
sanctions to enforce those rules (7). NormativeMay 2017systems of this nature have the advantage of
avoiding the high costs associated with legal
enforcement.
We see a strong analogy between Ellickson’s
ranchers and the biomedical research com-
munity. Although research communities are
not geographically defined, as in Ellickson’s
study, they display many of the same features:
Members frequently interact both privately
and publicly and share much the same sense
of mutual dependence, making noncom-
pliant members eligible for various informal
sanctions—such as exclusion from conferences
and failure to be credited in research articles.
These sanctions are likely to be more effective
than a remote threat of legal enforcement, giv-
en researchers’ and their institutions’ ongoing
need to maintain a profile in the community.
Thus, although the trust document might seem
to gesture toward a legal enforcement frame-
work as its backdrop, its more salient effect
comes from the same set of communal values
that the open science trust concept itself seeks
to promote.
Laws and norms also influence one another,
including in the area of biomedical research.
For example, scientific research norms histor-
ically promoted science in the public domain,
but the Bayh-Dole Act and associated laws
have partially subverted these norms in favor
of proprietary approaches (8). The open science
trust can be seen as an attempt to use law in-
stead to revive, reinforce, and extend the preex-
isting community norms around open science,
specifically in the context of sharing reagents.A SAMPLE OPEN SCIENCE
TRUST AGREEMENT
For the past 5 years, the Structural Genomics
Consortium has used a “click-wrap” MTA
(www.thesgc.org/chemical-probes/request)
to distribute material with minimal obliga-
tions. This MTA is principally designed to
protect this consortium against misuse of
the reagents. Although this MTA requires
the recipient to refrain from filing for intellec-
tual property protection covering the reagents,
and has been successfully used to distribute
thousands of reagents, it is structured as a bi-
lateral contract and does not create an ex-
panded community of researchers with a
shared commitment to open science. The open
science trust agreement (OSTA) is the first
attempt by the Structural Genomics Con-
sortium to deploy the open science trust mech-
anism to disseminate research tools (www.
thesgc.org/click-trust). In the OSTA, an intro-
ductory section first describes the organization,2 of 3
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 creates the trust, and sets out its beneficiaries,
which, in this instance, are the Structural
Genomics Consortium and its members, re-
searchers in the scientific community, and in-
dividuals in the general public who benefit
from research with the entrusted material.
A series of clauses then outlines the conditions
under which the material is transferred. The
main differences between a standard MTA
and the OSTA are that the OSTA (i) requires
the recipient trustee to commit not to file for
any intellectual property that covers aspects
of the material or its uses; (ii) requires the re-
cipient to place the results from the use of the
reagents into the public domain, through open
access journals or on openly accessible web-
sites, as rapidly as is possible; and (iii) grants
the recipient the right to disseminate the
material to additional recipients, provided those
recipients agree to the terms of the OSTA.
Most impediments to sharing research re-
agents, even those of no commercial value, de-
rive not from concerns about safety, research
primacy, or the public good but rather from
concerns about current and future ownership
of intellectual property. In early-stage drug dis-Edwards et al., Sci. Transl. Med. 9, eaai9055 (2017) 31covery research, the morass of agreements and
competing intellectual property claims can
hinder the progress of science and discovery.
We anticipate that the open science trust mech-
anism will reduce costly redundancies in early-
stage research and allow universities and
funders to quantify the broader returns on their
research investments.REFERENCES AND NOTES
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